Program
setidegrasib
Also written as “Setidegrasib” and “14C-labeled ASP3082”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Pancreatic Neoplasms · Neoplasms, led by Astellas Pharma.
Furthest: phase 3, since Feb 9, 20264 company-led studies, 3 open or runningNext primary completion: Dec 31, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Astellas Pharma | 43 open or running | phase 3since Feb 9, 2026 | May 16, 2022 | Dec 31, 2028phase 1 · NCT05382559 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 16, 2022First study: phase 1 study in NeoplasmsFirst studyNCT05382559 · 681 planned · United States, China, France and more
- Feb 9, 2026Phase 3 study in Pancreatic NeoplasmsPhase 3 reachedNCT07409272 · 614 planned · United States, Brazil, China and more
- Apr 27, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07566052 · 356 planned · United States, China, Japan
- Aug 16, 2026Phase 1 study in Healthy VolunteerNCT07773129 · 8 enrolled · United States
Ahead
- Dec 31, 2028Primary completion: phase 1 study in NeoplasmsNCT05382559
- Aug 31, 2029Primary completion: phase 3 study in Pancreatic NeoplasmsNCT07409272
- Jun 30, 2030Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07566052
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07773129Healthy Volunteer · United States | 1 | Completed | Oct 20, 2026 | 8 |
| NCT07566052Carcinoma, Non-Small-Cell Lung · United States, China, Japan | 3 | Recruiting | Jun 30, 2030 | 356 |
| NCT07409272Pancreatic Neoplasms · United States, Brazil, China and more | 3 | Recruiting | Aug 31, 2029 | 614 |
| NCT05382559Neoplasms · United States, China, France and more | 1 | Recruiting | Dec 31, 2028 | 681 |
How it is read
Names in the registry
- “Setidegrasib”, 3 entries
- “14C-labeled ASP3082”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
- Pancreatic Neoplasms, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.